NCT03840252

Brief Summary

This longitudinal study aims to research cognitive and gait phenotypes of Parkinson's disease and Supranuclear Palsy as well as to provide markers to track diseases progression using a multi-modality approach based on 3D-gait analysis and MR Imaging. Specifically, this study want to identify cognitive pattern and gait-related cerebral diffusion/functional connectivity in PD and PSP patients and to verify their progression over a period of 18 months. In summary, the current protocol proposed to investigate the following issues:

  • to perform a multifactorial quantitative analysis of outcomes for PD and PSP compared to a control group in order to categorize cognitive and gait pattern in the group of patients and verify if the gait can be useful as discriminator for diagnosis.
  • to analyze whether diffusion and resting-state functional connectivity indices are correlated with clinical disease severity scores and motor scores and how they change over time (18 months later).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
78

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Sep 2015

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 23, 2015

Completed
3.4 years until next milestone

First Submitted

Initial submission to the registry

February 11, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

February 15, 2019

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 25, 2019

Completed
6 days until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2019

Completed
Last Updated

April 10, 2024

Status Verified

May 1, 2020

Enrollment Period

3.8 years

First QC Date

February 11, 2019

Last Update Submit

April 9, 2024

Conditions

Keywords

3D-gait analysisMagnetic Resonance Imaging

Outcome Measures

Primary Outcomes (1)

  • Gait profile Score (GPS) in PD and PSP patients

    GPS quantifies the gait pattern deviation of the patient respect to normality range

    18 months

Study Arms (3)

PD patients: Parkinson's disease group

ACTIVE COMPARATOR

Diagnosis of idiopathic PD by United Kingdom Brain Bank criteria, exclusion of other significant neurological or orthopedic problems; ages of 21-90; able to walk 25 feet unassisted and without any assistive device. Imaging: rsfMRI, diffusion tensor imaging; Motor evaluation: 3D gait analysis; Movement Disorder Society (MDS)-UPDRS Behavioral: PD-MCI-specific Level II battery (Mov Dis. 2015 Mar; 30(3): 402-406)

Diagnostic Test: 3D gait analysisDiagnostic Test: rsfMRIDiagnostic Test: Montreal Cognitive assesment (MoCA)

PSP patients

ACTIVE COMPARATOR

Application of the National Institute of Neurological Disorders and Stroke and Society for Progressive Supranuclear Palsy (NINDS-SPSP) criteria for the clinical diagnosis of "probable" PSP, evaluation of PSP rating scale, exclusion of other significant neurological or orthopedic problems; ages of 21-90; able to walk 25 feet unassisted and without any assistive device. Imaging: rsfMRI, diffusion tensor imaging; Motor evaluation: 3D gait analysis;MDS-UPDRS Behavioral: PD-MCI-specific Level II battery (Mov Dis. 2015 Mar; 30(3): 402-406)

Diagnostic Test: 3D gait analysisDiagnostic Test: rsfMRIDiagnostic Test: Montreal Cognitive assesment (MoCA)

HC: healthy control group

ACTIVE COMPARATOR

Healthy adults ages 21-90 without movement disorders, psychiatric disorders, or dementia. Imaging: rsfMRI, diffusion tensor imaging; Motor evaluation: 3D gait analysis; Behavioral: PD-Mild Cognitive Impairment (MCI)-specific Level II battery (Mov Dis. 2015 Mar; 30(3): 402-406)

Diagnostic Test: 3D gait analysisDiagnostic Test: rsfMRIDiagnostic Test: Montreal Cognitive assesment (MoCA)

Interventions

3D gait analysisDIAGNOSTIC_TEST

Computed analysis of posture and gait pattern and motor performance by kinematic and kinetics parameters analysis such as the step length, gait velocity, stride time variability, 3D joint kinematics, ground reaction forces, joint kinetics

HC: healthy control groupPD patients: Parkinson's disease groupPSP patients
rsfMRIDIAGNOSTIC_TEST

MR scans acquired by 1.5 Tesla (Siemens Medical Systems, Erlangen, Germany).

Also known as: resting state functional magnetic resonance (rsfMRI)
HC: healthy control groupPD patients: Parkinson's disease groupPSP patients

Standard clinical questionnaire

HC: healthy control groupPD patients: Parkinson's disease groupPSP patients

Eligibility Criteria

Age20 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosis of idiopathic PD by United Kingdom (UK) Brain Bank criteria and PSP according to NINDS-SPSP criteria, without other significant neurological or orthopedic problems;
  • ages of 20-80;
  • able to walk 25 feet unassisted and without any assistive device

You may not qualify if:

  • History of epileptic seizures, head injury, other neurological disorders.
  • Cardiac pacemaker implantation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Casa di cura San Raffaele Cassino

Cassino, Frosinone, Italy

Location

MeSH Terms

Conditions

Parkinson DiseaseParalysis

Condition Hierarchy (Ancestors)

Parkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative DiseasesNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Fabrizio Stocchi, MD, PhD

    IRCCS San Raffaele Pisana

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 11, 2019

First Posted

February 15, 2019

Study Start

September 23, 2015

Primary Completion

July 25, 2019

Study Completion

July 31, 2019

Last Updated

April 10, 2024

Record last verified: 2020-05

Data Sharing

IPD Sharing
Will not share

Locations